NR3C2 and heart failure: On the other hand, a meta-analysis of seven randomized controlled trials evaluating the impact of MR antagonists on cardiovascular mortality and morbidity outcomes in patients with heart failure and/or left ventricular systolic dysfunction aged ≥65 years, did not confirm significant improvement in clinical outcomes among patients with HFpEF.